{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:06:16Z","timestamp":1790787976729,"version":"4.1.0"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008081","name":"Southeast University","doi-asserted-by":"publisher","award":["2242025RCB0054"],"award-info":[{"award-number":["2242025RCB0054"]}],"id":[{"id":"10.13039\/501100008081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82570816"],"award-info":[{"award-number":["82570816"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20240212"],"award-info":[{"award-number":["BK20240212"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejim.2025.106506","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T22:37:25Z","timestamp":1758062245000},"page":"106506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Anemia in cardiorenal disease: From pathogenesis to treatment"],"prefix":"10.1016","volume":"143","author":[{"given":"Juan","family":"Heng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Tang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Dan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Xuan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuo-Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejim.2025.106506_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"10.1016\/j.ejim.2025.106506_bib0002","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41572-024-00589-9","article-title":"Chronic kidney disease","volume":"11","author":"Romagnani","year":"2025","journal-title":"Nat Rev Dis Primers"},{"issue":"10431","key":"10.1016\/j.ejim.2025.106506_bib0003","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0140-6736(23)02756-3","article-title":"Heart failure with preserved ejection fraction: everything the clinician needs to know","volume":"403","author":"Campbell","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejim.2025.106506_bib0004","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027852","article-title":"Burden, trends, and inequalities of heart failure globally, 1990 to 2019: a secondary analysis based on the global burden of disease 2019 study","volume":"12","author":"Yan","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.ejim.2025.106506_bib0005","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2215\/CJN.0000000000000361","article-title":"From cardiorenal syndrome to chronic cardiovascular and kidney disorder: a conceptual transition","volume":"19","author":"Zoccali","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.ejim.2025.106506_bib0006","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/CIRCRESAHA.122.321762","article-title":"Hypertension as cardiovascular risk factor in chronic kidney disease","volume":"132","author":"Burnier","year":"2023","journal-title":"Circ Res"},{"issue":"12","key":"10.1016\/j.ejim.2025.106506_bib0007","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: improving Global Outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.ejim.2025.106506_bib0008","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41581-022-00616-6","article-title":"Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease","volume":"18","author":"Matsushita","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"10.1016\/j.ejim.2025.106506_bib0009","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/cvr\/cvad083","article-title":"Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association","volume":"119","author":"Zoccali","year":"2023","journal-title":"Cardiovasc Res"},{"issue":"2","key":"10.1016\/j.ejim.2025.106506_bib0010","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10741-023-10346-x","article-title":"Assessment and management of heart failure in patients with chronic kidney disease","volume":"29","author":"Guaricci","year":"2024","journal-title":"Heart Fail Rev"},{"issue":"4","key":"10.1016\/j.ejim.2025.106506_bib0011","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/jamainternmed.2022.6817","article-title":"Prevalence of chronic kidney disease in China: results from the sixth China chronic disease and risk factor surveillance","volume":"183","author":"Wang","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"10","key":"10.1016\/j.ejim.2025.106506_bib0012","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrneph.2016.113","article-title":"von Haehling S. Heart failure and kidney dysfunction: epidemiology, mechanisms and management","volume":"12","author":"Schefold","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"10.1016\/j.ejim.2025.106506_bib0013","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jacc.2008.10.046","article-title":"Anemia: the point of convergence or divergence for kidney disease and heart failure?","volume":"53","author":"Kazory","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ejim.2025.106506_bib0014","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ckj\/sfz091","article-title":"Pisoni RL; CKDopps Investigators. Anemia and iron deficiency among chronic kidney disease stages 3-5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated","volume":"13","author":"Wong","year":"2019","journal-title":"Clin Kidney J"},{"issue":"2","key":"10.1016\/j.ejim.2025.106506_bib0015","doi-asserted-by":"crossref","DOI":"10.1111\/nep.70002","article-title":"Prevalence and treatment patterns of anaemia in individuals with chronic kidney disease across Asia: a systematic review and meta-analysis","volume":"30","author":"Kim","year":"2025","journal-title":"Nephrology (Carlton)"},{"issue":"7","key":"10.1016\/j.ejim.2025.106506_bib0016","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0735-1097(00)00613-6","article-title":"The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations","volume":"35","author":"Silverberg","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ejim.2025.106506_bib0017","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000443339","article-title":"Impact of cardiorenal anemia syndrome on short- and long-term clinical outcomes in patients hospitalized with heart failure","volume":"6","author":"Kim","year":"2016","journal-title":"Cardiorenal Med"},{"issue":"1","key":"10.1016\/j.ejim.2025.106506_bib0018","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.kisu.2020.12.001","article-title":"Anemia of cardiorenal syndrome","volume":"11","author":"McCullough","year":"2021","journal-title":"Kidney Int Suppl"},{"issue":"5","key":"10.1016\/j.ejim.2025.106506_bib0019","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.037363","article-title":"Anemia management in the cardiorenal patient: a nephrological perspective","volume":"14","author":"Marques Vidas","year":"2025","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.ejim.2025.106506_bib0020","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10741-011-9230-x","article-title":"Anemia in cardio-renal syndrome: clinical impact and pathophysiologic mechanisms","volume":"16","author":"Palazzuoli","year":"2011","journal-title":"Heart Fail Rev"},{"issue":"2","key":"10.1016\/j.ejim.2025.106506_bib0021","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/j.ajkd.2014.12.016","article-title":"Goldsmith D. Cardiorenal syndrome and the role of the bone-mineral axis and anemia","volume":"66","author":"Charytan","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.ejim.2025.106506_bib0022","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3390\/biomedicines13020462","article-title":"Targeting inflammation and iron deficiency in heart failure: a focus on older adults","volume":"13","author":"Maidana","year":"2025","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.ejim.2025.106506_bib0023","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00392-023-02275-4","article-title":"The treatment of chronic anemia in heart failure: a global approach","volume":"113","author":"Bianchi","year":"2024","journal-title":"Clin Res Cardiol"},{"issue":"2","key":"10.1016\/j.ejim.2025.106506_bib0024","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1042\/CS20100305","article-title":"Erythropoietin and the heart: facts and perspectives","volume":"120","author":"Mastromarino","year":"2011","journal-title":"Clin Sci (Lond)"},{"issue":"10","key":"10.1016\/j.ejim.2025.106506_bib0025","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41581-019-0182-z","article-title":"Mechanisms of hypoxia signalling: new implications for nephrology","volume":"15","author":"Sch\u00f6del","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"13\u201315","key":"10.1016\/j.ejim.2025.106506_bib0026","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1089\/ars.2021.0271","article-title":"Disturbance of hypoxia response and its implications in kidney diseases","volume":"37","author":"Li","year":"2022","journal-title":"Antioxid Redox Signal"},{"issue":"7","key":"10.1016\/j.ejim.2025.106506_bib0027","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/ejhf.484","article-title":"High serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria: data from PREVEND","volume":"18","author":"Grote Beverborg","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.ejim.2025.106506_bib0028","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002124","article-title":"Association of serum erythropoietin with cardiovascular events, kidney function decline, and mortality: the health aging and body composition study","volume":"9","author":"Garimella","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.ejim.2025.106506_bib0029","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004431","article-title":"Hyporesponsiveness to Darbepoetin Alfa in patients with heart failure and anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): clinical and prognostic associations","volume":"11","author":"van der Meer","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"13","key":"10.1016\/j.ejim.2025.106506_bib0030","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","article-title":"RED-HF investigators. Treatment of anemia with darbepoetin alfa in systolic heart failure","volume":"368","author":"Swedberg","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejim.2025.106506_bib0031","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000504850","article-title":"Treatment of renal anemia with roxadustat: advantages and achievement","volume":"6","author":"Li","year":"2020","journal-title":"Kidney Dis (Basel)"},{"issue":"2","key":"10.1016\/j.ejim.2025.106506_bib0032","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000536039","article-title":"Stabilizing hypoxia-inducible factor to manage anemia in chronic kidney disease: from basic theory to clinical study","volume":"10","author":"Wang","year":"2024","journal-title":"Kidney Dis (Basel)"},{"issue":"1","key":"10.1016\/j.ejim.2025.106506_bib0033","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.030099","article-title":"Anemia and iron deficiency in heart failure: current concepts and emerging therapies","volume":"138","author":"Anand","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ejim.2025.106506_bib0034","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/ehf2.15157","article-title":"Iron deficiency in heart failure: epidemiology, diagnostic criteria and treatment modalities","volume":"12","author":"von Haehling","year":"2025","journal-title":"ESC Heart Fail"},{"issue":"2","key":"10.1016\/j.ejim.2025.106506_bib0035","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/CIRCULATIONAHA.124.068883","article-title":"Redefining iron deficiency in patients with chronic heart failure","volume":"150","author":"Packer","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2025.106506_bib0036","doi-asserted-by":"crossref","DOI":"10.2174\/011573403X351268250130070459","article-title":"Prevalence and adverse outcomes of iron deficiency in heart failure","author":"Habeeb","year":"2025","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.ejim.2025.106506_bib0037","article-title":"Associations of iron deficiency with cardiac function, congestion, exercise capacity and prognosis in heart failure","author":"De Biase","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"10.1016\/j.ejim.2025.106506_bib0038","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/ejhf.2879","article-title":"Iron deficiency in heart failure: screening, prevalence, incidence and outcome data from the Swedish Heart Failure Registry and the Stockholm CREAtinine Measurements collaborative project","volume":"25","author":"Lindberg","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10.1016\/j.ejim.2025.106506_bib0039","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.032540","article-title":"Imbalance of iron availability and demand in patients with acute and chronic heart failure","volume":"13","author":"Lanser","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.ejim.2025.106506_bib0040","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/ajh.21902","article-title":"Afshar-Kharghan V. Hepcidin in anemia of chronic heart failure","volume":"86","author":"Divakaran","year":"2011","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.ejim.2025.106506_bib0041","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/eurjhf\/hfq099","article-title":"Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease\/chronic heart failure patients","volume":"12","author":"van der Putten","year":"2010","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.ejim.2025.106506_bib0042","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/ejhf.2454","article-title":"Cardiac energetics in patients with chronic heart failure and iron deficiency: an in-vivo (31) P magnetic resonance spectroscopy study","volume":"24","author":"Papalia","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.ejim.2025.106506_bib0043","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/ejhf.640","article-title":"Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis","volume":"19","author":"Melenovsky","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10.1016\/j.ejim.2025.106506_bib0044","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ejhf.1154","article-title":"Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function","volume":"20","author":"Hoes","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10.1016\/j.ejim.2025.106506_bib0045","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.3390\/cells9092039","article-title":"Uremic toxins affect erythropoiesis during the course of chronic kidney disease: a review","volume":"9","author":"Hamza","year":"2020","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.ejim.2025.106506_bib0046","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.etp.2014.01.003","article-title":"Uremic toxins impair human bone marrow-derived mesenchymal stem cells functionality in vitro","volume":"66","author":"Idziak","year":"2014","journal-title":"Exp Toxicol Pathol"},{"issue":"7","key":"10.1016\/j.ejim.2025.106506_bib0047","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/eurjhf\/hfq061","article-title":"Bone marrow dysfunction in chronic heart failure patients","volume":"12","author":"Westenbrink","year":"2010","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10.1016\/j.ejim.2025.106506_bib0048","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/ndt\/gft021","article-title":"Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation","volume":"28","author":"Icardi","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1016\/j.ejim.2025.106506_bib0049","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jchf.2022.12.012","article-title":"Prevalent and incident anemia in PARADIGM-HF and the effect of Sacubitril\/Valsartan","volume":"11","author":"Curtain","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"11","key":"10.1016\/j.ejim.2025.106506_bib0050","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1097\/HJH.0000000000002111","article-title":"Inhibition of the renin-angiotensin system in the cardiorenal syndrome with anaemia: a double-edged sword","volume":"37","author":"Vlahakos","year":"2019","journal-title":"J Hypertens"},{"issue":"1","key":"10.1016\/j.ejim.2025.106506_bib0051","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ncpneph0655","article-title":"Mechanisms of disease: erythropoietin resistance in patients with both heart and kidney failure","volume":"4","author":"van der Putten","year":"2008","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.ejim.2025.106506_bib0052","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/405016","article-title":"Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis","volume":"2009","author":"Morceau","year":"2009","journal-title":"Mediators Inflamm"},{"issue":"5","key":"10.1016\/j.ejim.2025.106506_bib0053","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196684","article-title":"The hypoxia inducible factor\/erythropoietin (EPO)\/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia","volume":"13","author":"Landau","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ejim.2025.106506_bib0054","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1159\/000081058","article-title":"Anemia and diabetes","volume":"24","author":"Deray","year":"2004","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1016\/j.ejim.2025.106506_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100947","article-title":"EPO-mimetic peptide pegmolesatide therapy for pure red cell aplasia in a patient with non-dialysis-dependent type 1 diabetic nephropathy: a case report","volume":"7","author":"Chen","year":"2024","journal-title":"Kidney Med"},{"issue":"4","key":"10.1016\/j.ejim.2025.106506_bib0056","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0272-6386(04)00951-5","article-title":"Red blood cell survival in chronic renal failure","volume":"44","author":"Ly","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.ejim.2025.106506_bib0057","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.ajkd.2011.03.031","article-title":"Red blood cell survival in long-term dialysis patients","volume":"58","author":"Vos","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1016\/j.ejim.2025.106506_bib0058","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1159\/000502525","article-title":"Red blood cell lifespan shortening in patients with early-stage chronic kidney disease","volume":"44","author":"Li","year":"2019","journal-title":"Kidney Blood Press Res"},{"issue":"6","key":"10.1016\/j.ejim.2025.106506_bib0059","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.kint.2021.08.024","article-title":"Proteinuric chronic kidney disease is associated with altered red blood cell lifespan, deformability and metabolism","volume":"100","author":"Bissinger","year":"2021","journal-title":"Kidney Int"},{"issue":"24","key":"10.1016\/j.ejim.2025.106506_bib0060","doi-asserted-by":"crossref","first-page":"7373","DOI":"10.3390\/jcm11247373","article-title":"Association of red blood cell life span with abnormal changes in cardiac structure and function in non-dialysis patients with chronic kidney disease stages 3-5","volume":"11","author":"Rao","year":"2022","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.ejim.2025.106506_bib0061","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.blre.2017.06.001","article-title":"Eryptosis in health and disease: a paradigm shift towards understanding the (patho)physiological implications of programmed cell death of erythrocytes","volume":"31","author":"Qadri","year":"2017","journal-title":"Blood Rev"},{"issue":"8","key":"10.1016\/j.ejim.2025.106506_bib0062","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00109-014-1151-4","article-title":"Suicidal erythrocyte death in end-stage renal disease","volume":"92","author":"Abed","year":"2014","journal-title":"J Mol Med (Berl)"},{"issue":"11","key":"10.1016\/j.ejim.2025.106506_bib0063","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/ndt\/12.11.2375","article-title":"The required dose of erythropoietin during renal anaemia treatment is related to the degree of impairment in erythrocyte deformability","volume":"12","author":"Linde","year":"1997","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.ejim.2025.106506_bib0064","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000044878","article-title":"Red blood cell osmotic fragility in chronically hemodialyzed patients","volume":"78","author":"Wu","year":"1998","journal-title":"Nephron"},{"issue":"12","key":"10.1016\/j.ejim.2025.106506_bib0065","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1007\/s11255-023-03566-5","article-title":"Association of malnutrition with all-cause and cardiovascular mortality in patients with mild to severe chronic kidney disease undergoing coronary angiography: a large multicenter longitudinal study","volume":"55","author":"Gao","year":"2023","journal-title":"Int Urol Nephrol"},{"issue":"9","key":"10.1016\/j.ejim.2025.106506_bib0066","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/hr.2016.47","article-title":"Malnutrition, renal dysfunction and left ventricular hypertrophy synergistically increase the long-term incidence of cardiovascular events","volume":"39","author":"Maruyama","year":"2016","journal-title":"Hypertens Res"},{"issue":"12","key":"10.1016\/j.ejim.2025.106506_bib0067","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1007\/s11255-023-03566-5","article-title":"Association of malnutrition with all-cause and cardiovascular mortality in patients with mild to severe chronic kidney disease undergoing coronary angiography: a large multicenter longitudinal study","volume":"55","author":"Gao","year":"2023","journal-title":"Int Urol Nephrol"},{"issue":"12","key":"10.1016\/j.ejim.2025.106506_bib0068","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1161\/CIRCULATIONAHA.105.549121","article-title":"Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure","volume":"112","author":"van der Meer","year":"2005","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ejim.2025.106506_bib0069","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2004.10.038","article-title":"Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction","volume":"45","author":"Ishani","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.ejim.2025.106506_bib0070","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/eurheartj\/ehl012","article-title":"The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET","volume":"27","author":"Komajda","year":"2006","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ejim.2025.106506_bib0071","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kisu.2020.12.006","article-title":"Treatment of anemia in difficult-to-manage patients with chronic kidney disease","volume":"11","author":"Raichoudhury","year":"2011","journal-title":"Kidney Int Suppl"},{"issue":"6","key":"10.1016\/j.ejim.2025.106506_bib0072","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.kint.2019.02.022","article-title":"Conference participants. Heart failure in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies Conference","volume":"95","author":"House","year":"2019","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejim.2025.106506_bib0073","article-title":"Kidney disease: improving global Outcomes (KDIGO) anemia work group. KDIGO 2025 clinical practice guideline for anemia in chronic kidney disease","year":"2025","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.ejim.2025.106506_bib0074","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2215\/CJN.02730608","article-title":"Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis","volume":"4","author":"Parfrey","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2025.106506_bib0075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijcard.2016.04.187","article-title":"The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: a meta-analysis of randomized clinical trials","volume":"218","author":"Kang","year":"2016","journal-title":"Int J Cardiol"},{"issue":"12","key":"10.1016\/j.ejim.2025.106506_bib0076","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1056\/NEJMoa1005109","article-title":"Trial to reduce cardiovascular events with Aranesp Therapy (TREAT) investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes","volume":"363","author":"Solomon","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejim.2025.106506_bib0077","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1159\/000351175","article-title":"Califf RM. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease","volume":"37","author":"McCullough","year":"2013","journal-title":"Am J Nephrol"},{"issue":"18","key":"10.1016\/j.ejim.2025.106506_bib0078","first-page":"e895","article-title":"ACC\/AHA Joint Committee members. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"37","key":"10.1016\/j.ejim.2025.106506_bib0079","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"issue":"10369","key":"10.1016\/j.ejim.2025.106506_bib0080","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","article-title":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Kalra","year":"2022","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.ejim.2025.106506_bib0081","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejim.2025.106506_bib0082","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.2215\/CJN.0000000000000223","article-title":"Ferric Carboxymaltose in iron-deficient patients with hospitalized heart failure and reduced kidney function","volume":"18","author":"Macdougall","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"48","key":"10.1016\/j.ejim.2025.106506_bib0083","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1093\/eurheartj\/ehad586","article-title":"Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis","volume":"44","author":"Ponikowski","year":"2023","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.ejim.2025.106506_bib0084","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.jchf.2024.05.014","article-title":"Management of iron deficiency in heart failure: practical considerations and implementation of evidence-based iron supplementation","volume":"12","author":"Kido","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10.1016\/j.ejim.2025.106506_bib0085","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ehf2.14905","article-title":"Intravenous iron therapy for heart failure and iron deficiency: an updated meta-analysis of randomized clinical trials","volume":"12","author":"Ahmed","year":"2025","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2025.106506_bib0086","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03671-1","article-title":"Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency","author":"Anker","year":"2025","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ejim.2025.106506_bib0087","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000433564","article-title":"Target hemoglobin may be achieved with intravenous iron alone in anemic patients with cardiorenal syndrome: an observational study","volume":"5","author":"Ben-Assa","year":"2015","journal-title":"Cardiorenal Med"},{"issue":"22","key":"10.1016\/j.ejim.2025.106506_bib0088","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.122.060757","article-title":"AFFIRM-AHF Investigators. Association between hemoglobin levels and efficacy of intravenous Ferric carboxymaltose in patients with acute heart failure and iron deficiency: an AFFIRM-AHF subgroup analysis","volume":"147","author":"Filippatos","year":"2023","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ejim.2025.106506_bib0089","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Ford I; PIVOTAL Investigators and Committees. Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ejim.2025.106506_bib0090","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/nep.12940","article-title":"Intravenous iron and erythropoiesis-stimulating agents in haemodialysis: a systematic review and meta-analysis","volume":"22","author":"Roger","year":"2017","journal-title":"Nephrology (Carlton)"},{"issue":"5","key":"10.1016\/j.ejim.2025.106506_bib0091","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1053\/j.ajkd.2016.04.018","article-title":"Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis","volume":"68","author":"Shepshelovich","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"19","key":"10.1016\/j.ejim.2025.106506_bib0092","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1001\/jama.2017.5427","article-title":"NHLBI Heart Failure Clinical Research Network. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial","volume":"317","author":"Lewis","year":"2017","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ejim.2025.106506_bib0093","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa2304968","article-title":"HEART-FID investigators. Ferric Carboxymaltose in heart failure with iron deficiency","volume":"389","author":"Mentz","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106506_bib0094","article-title":"Intravenous ferric carboxymaltose in heart failure with iron deficiency: the FAIR-HF2 DZHK05 randomized clinical trial","author":"Anker","year":"2025","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ejim.2025.106506_bib0095","doi-asserted-by":"crossref","first-page":"354","DOI":"10.17305\/bb.2022.8437","article-title":"Roxadustat: do we know all the answers?","volume":"23","author":"Li","year":"2023","journal-title":"Biomol Biomed"},{"issue":"4","key":"10.1016\/j.ejim.2025.106506_bib0096","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf061","article-title":"Efficacy and safety of roxadustat for treating anaemia in patients with chronic kidney disease and heart failure: a retrospective cohort study","volume":"18","author":"Liu","year":"2025","journal-title":"Clin Kidney J"},{"issue":"4","key":"10.1016\/j.ejim.2025.106506_bib0097","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e15310","article-title":"Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on iron metabolism and inflammation in patients undergoing dialysis: a systematic review and meta-analysis","volume":"9","author":"Zheng","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.ejim.2025.106506_bib0098","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105256","article-title":"Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: a systematic review and meta-analysis","volume":"163","author":"Li","year":"2021","journal-title":"Pharmacol Res"},{"issue":"3","key":"10.1016\/j.ejim.2025.106506_bib0099","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000538372","article-title":"Roxadustat on renal anemia with macroinflammation: a retrospective cohort study","volume":"10","author":"Tu","year":"2024","journal-title":"Kidney Dis (Basel)"},{"issue":"11","key":"10.1016\/j.ejim.2025.106506_bib0100","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106506_bib0101","article-title":"Effects of roxadustat on anemia, iron metabolism, and lipid metabolism in patients with non-dialysis chronic kidney disease","volume":"10","author":"Hirai","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"22","key":"10.1016\/j.ejim.2025.106506_bib0102","doi-asserted-by":"crossref","first-page":"9382","DOI":"10.1074\/jbc.M117.788562","article-title":"Hypoxia-inducible factor 1alpha activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver","volume":"292","author":"Hwang","year":"2017","journal-title":"J Biol Chem"},{"issue":"Pt 14","key":"10.1016\/j.ejim.2025.106506_bib0103","first-page":"3485","article-title":"Hypoxia causes triglyceride accumulation by HIF-1-mediated stimulation of lipin 1 expression","volume":"125","author":"Mylonis","year":"2012","journal-title":"J Cell Sci"},{"issue":"1","key":"10.1016\/j.ejim.2025.106506_bib0104","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12964-025-02175-2","article-title":"The roxadustat (FG-4592) ameliorates tubulointerstitial fibrosis by promoting intact FGF23 cleavage","volume":"23","author":"Wang","year":"2025","journal-title":"Cell Commun Signal"},{"issue":"4","key":"10.1016\/j.ejim.2025.106506_bib0105","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.kint.2023.05.009","article-title":"for conference participants. Novel anemia therapies in chronic kidney disease: conclusions from a Kidney disease: improving global outcomes (KDIGO) Controversies conference","volume":"104","author":"Ku","year":"2023","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.ejim.2025.106506_bib0106","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1681\/ASN.0000000000000321","article-title":"Daprodustat and heart failure in CKD","volume":"35","author":"Cunningham","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.ejim.2025.106506_bib0107","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300049","article-title":"Dapagliflozin and anemia in patients with chronic kidney disease","volume":"2","author":"Koshino","year":"2023","journal-title":"NEJM Evid"},{"issue":"2","key":"10.1016\/j.ejim.2025.106506_bib0108","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ejhf.2735","article-title":"Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial","volume":"25","author":"Fuchs Andersen","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.ejim.2025.106506_bib0109","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1002\/jcp.30851","article-title":"Sodium-glucose co-transporter 2 inhibitors and hematopoiesis","volume":"237","author":"Yaribeygi","year":"2022","journal-title":"J Cell Physiol"},{"issue":"11","key":"10.1016\/j.ejim.2025.106506_bib0110","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jchf.2023.07.010","article-title":"DAPA-VO2 investigators. Short-term changes in peak VO(2) after initiation of Dapagliflozin in heart failure across iron status","volume":"11","author":"Lorenzo","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"12","key":"10.1016\/j.ejim.2025.106506_bib0111","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ejhf.2992","article-title":"Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium-glucose cotransporter 2 inhibitors","volume":"25","author":"Marques","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.ejim.2025.106506_bib0112","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cardfail.2022.12.007","article-title":"Combining iron supplements with SGLT2 inhibitor-stimulated erythropoiesis in heart failure: should we be worried about thromboembolic events?","volume":"29","author":"Packer","year":"2023","journal-title":"J Card Fail"},{"issue":"3","key":"10.1016\/j.ejim.2025.106506_bib0113","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212023","article-title":"First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis","volume":"14","author":"Renders","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejim.2025.106506_bib0114","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1681\/ASN.0000000000000245","article-title":"Effect of Ziltivekimab on determinants of hemoglobin in patients with CKD stage 3-5: an analysis of a randomized trial (RESCUE)","volume":"35","author":"Pergola","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.ejim.2025.106506_bib0115","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1681\/ASN.0000000654","article-title":"on behalf of the POSIBIL ESKD Investigators. Effects of Clazakizumab on anemia and iron metabolism in patients with kidney failure","volume":"36","author":"Neuen","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2025.106506_bib0116","article-title":"Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial","volume":"65","author":"Zhang","year":"2023","journal-title":"E Clinic Med"},{"issue":"3","key":"10.1016\/j.ejim.2025.106506_bib0117","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ekir.2024.12.002","article-title":"Randomized trial of Pegmolesatide for the treatment of anemia in patients with nondialysis CKD","volume":"10","author":"Xie","year":"2024","journal-title":"Kidney Int Rep"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362052500384X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362052500384X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T09:24:05Z","timestamp":1772875445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095362052500384X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":117,"alternative-id":["S095362052500384X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2025.106506","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anemia in cardiorenal disease: From pathogenesis to treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2025.106506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106506"}}